Discovered in July, 3I/ATLAS is not your average comet – it’s a giant snowball from beyond our solar system. The comet, ...

The most sensational story of the year for astronomers has been the discovery of the comet 3I/ATLAS, which was first observed on July 1, 2025 by NASA's Asteroid Terrestrial-impact Last Alert System ...

Comet 3I/ATLAS, also known as C/2025 N1 (ATLAS), is an interstellar comet that made headlines after its discovery in July 2025. Scientists believe it could be at least 7 billion years old. Comet 3I ...

3I/ATLAS has now made its closest approach to the sun and Earth and is now heading back out toward the outer solar system. When you purchase through links on our site, we may earn an affiliate ...

The third interstellar visitor, 3I/ATLAS, came into our solar system this summer. It did more than just set off astronomical alerts; it made us even more curious about what lies beyond our own sun.

On Dec. 19, 2025, 3I/ATLAS flew by Earth and did more than just give astronomers something to look at; it brought a piece of a far-off, alien world into our backyard. This cosmic vagabond moves at an ...

The interstellar object 3I/ATLAS, captured by the James Webb Space Telescope. Imagine an object sailing through the black void, a piece of cosmic shrapnel that was formed in a star system light years ...

The interstellar comet will pass safely by Earth, giving astronomers their best chance to study it up close. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

WASHINGTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- DigitalNet.ai today announced the official launch of ATLAS (Advanced Threat and Lifecycle Assurance System), a next-generation autonomous cybersecurity ...

A stray comet from another star is swinging past Earth this week in one last visible hurrah before it races back toward interstellar space. Discovered over the summer, the comet, officially designated ...

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...